公开(公告)号：US20210317224A1

公开(公告)日：2021-10-14

申请号：US17286437

申请日：2020-08-12

Applicant: I-Mab Biopharma US Limited ,  ABL Bio Inc.

Inventor： Wenqing Jiang ,  Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Eunyoung Park ,  Eunsil Sung ,  Byungje Sung

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

公开(公告)号：US10973853B2

公开(公告)日：2021-04-13

申请号：US16483870

申请日：2019-02-11

Applicant: I-Mab Biopharma US Limited

Inventor： Feifei Cui ,  Lei Fang ,  Bingshi Guo ,  Zhengyi Wang ,  Jingwu Zang

IPC: A61K39/00 ,  A61K35/17 ,  A61P31/18 ,  A61P35/00 ,  C07K16/28

Abstract: The present disclosure provides antibodies and fragments thereof having specificity to a human T cell immunoreceptor with Ig and ITIM domains (TIGIT) protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and viral infections are also provided.

公开(公告)号：US20210054093A1

公开(公告)日：2021-02-25

申请号：US16989702

申请日：2020-08-10

Applicant: I-Mab Biopharma US Limited

Inventor： Zhengyi Wang ,  Lei Fang ,  Bingshi Guo ,  Jingwu Zang

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  C07K16/30 ,  G01N33/68

Abstract: The present invention provides novel CD47 antibodies or immunologically active fragments thereof that have low immunogenicity in humans and cause low or no level of red blood cell depletion or hemagglutination, as well as pharmaceutical compositions containing such antibodies that can be used for treatment diseases mediated by CD47 or inhibition of phagocytosis or platelet aggregation.

公开(公告)号：US20210015858A1

公开(公告)日：2021-01-21

申请号：US16483870

申请日：2019-02-11

Applicant: I-MAB BIOPHARMA US LIMITED

Inventor： Feifei Cui ,  Lei Fang ,  Bingshi Guo ,  Zhengyi Wang ,  Jingwu Zang

IPC: A61K35/17 ,  C07K16/28 ,  A61P31/18 ,  A61P35/00

Abstract: The present disclosure provides antibodies and fragments thereof having specificity to a human T cell immunoreceptor with Ig and ITIM domains (TIGIT) protein. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and viral infections are also provided.

公开(公告)号：US20200317789A1

公开(公告)日：2020-10-08

申请号：US16909400

申请日：2020-06-23

Applicant: I-MAB Biopharma US Limited

Inventor： Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Jingwu Zang

IPC: C07K16/28 ,  A61P31/20 ,  A61P31/14 ,  A61P35/00 ,  A61P35/02 ,  A61P31/18 ,  A61P31/22 ,  A61P31/08 ,  A61P31/04 ,  A61P31/06 ,  A61P31/16 ,  A61K35/17

Abstract: Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

公开(公告)号：US11613577B2

公开(公告)日：2023-03-28

申请号：US16785953

申请日：2020-02-10

Applicant: I-MAB Biopharma US Limited

Inventor： Zhengyi Wang ,  Lei Fang ,  Bingshi Guo ,  Jingwu Zang

IPC: C07K16/00 ,  C07K16/28 ,  A61P35/00 ,  A61K9/00 ,  A61K9/06 ,  A61K35/17 ,  A61K39/395 ,  C07K16/40 ,  G01N33/574 ,  A61K39/00

Abstract: Provided are anti-CD73 antibodies or fragments thereof. The antibodies or fragments therefore include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. More generally, antibodies or fragments thereof are described which have specificity to one or more amino acid residues selected from the C-terminal half of a human CD73 protein, such as those in the C-terminal domains. Specific epitope amino acids in these domains include Y345, D399, E400, R401 and R480. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer are also provided.

公开(公告)号：US20220348675A1

公开(公告)日：2022-11-03

申请号：US17683869

申请日：2022-03-01

Applicant: I-Mab Biopharma US Limited ,  ABL Bio Inc.

Inventor： Wenqing Jiang ,  Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Eunyoung Park ,  Eunsil Sung ,  Byungje Sung

IPC: C07K16/28 ,  A61P35/00

Abstract: Provided are bispecific and multi-specific antibodies that target both claudin 18.2 (CLDN18.2) and 4-1BB. These antibodies, in the absence of CLDN18.2-expressing cells, can bind to 4-1BB but are unable to activate 4-1BB signaling. In the presence of CLDN18.2-expressing cells, however, these antibodies can trigger CLDN18.2-dependent 4-1BB signaling, leading to potent immune response to the CLDN18.2-expressing tumor cells.

公开(公告)号：US20210269522A1

公开(公告)日：2021-09-02

申请号：US17257294

申请日：2019-10-31

Applicant: I-Mab Biopharma US Limited

Inventor： Zhengyi Wang ,  Wei Cao ,  Lei Fang ,  Bingshi Guo

IPC: C07K16/28 ,  A61P35/00 ,  C07K14/535 ,  C12N9/80

Abstract: Provided are pharmaceutical compositions each comprising a glycosylation agent, an antibody that binds to human CD47, and a pharmaceutically acceptable carrier. Also provided are novel CD47 antibodies that bind to human CD47, wherein the antibodies bind to at least one epitope that is at one of the glycosylation sites of the CD47 protein of red blood cells (e. g, at least a glycosylation site near the epitope residues Gln31 and Thr34 in CD47).

公开(公告)号：US20230393144A1

公开(公告)日：2023-12-07

申请号：US18031858

申请日：2021-10-14

Applicant: I-MAB BIOPHARMA US LIMITED

Inventor： Wei Cao ,  Zhengyi Wang ,  Yanni Zhang ,  Bingshi Guo

IPC: G01N33/68 ,  G01N33/543 ,  G01N33/569 ,  C07K16/28 ,  C07K16/42

CPC classification number: G01N33/686 ,  G01N33/54393 ,  G01N33/56966 ,  C07K16/2803 ,  C07K16/4258 ,  C07K2317/76 ,  C07K2317/52 ,  C07K2317/92 ,  C07K2317/54

Abstract: Provided herein are methods of mitigating (such as eliminating) interference in a serological assay caused by a therapeutic anti-CD47 antibody. Also provided are anti-idiotypic antibodies for use in such methods. Also provided are methods of transfusing donor blood to a subject who is under treatment with a therapeutic anti-CD47 antibody.

公开(公告)号：US11414485B2

公开(公告)日：2022-08-16

申请号：US16687387

申请日：2019-11-18

Applicant: I-MAB Biopharma US Limited

Inventor： Lei Fang ,  Zhengyi Wang ,  Bingshi Guo ,  Jingwu Zang ,  Wenqing Jiang ,  Yongqiang Wang

IPC: C07K16/28 ,  A61P35/00 ,  A61P37/04 ,  A61K35/17 ,  A61K39/00

Abstract: The present disclosure provides antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease.